Dagmar Sedding
Overview
Explore the profile of Dagmar Sedding including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
28
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
von Hessert-Vaudoncourt C, Lelek S, Geisler C, Hartung T, Broker V, Briest F, et al.
Front Pharmacol
. 2024 Feb;
15:1308686.
PMID: 38375032
Somatostatin analogues (SSAs) are commonly used in the treatment of hormone hypersecretion in neuroendocrine tumors (NETs), however the extent to which they inhibit proliferation is much discussed. We studied the...
2.
Briest F, Koziolek E, Albrecht J, Schmidt F, Bernsen M, Haeck J, et al.
Neoplasia
. 2020 Nov;
23(1):80-98.
PMID: 33246310
Background: Well-differentiated gastroenteropancreatic neuroendocrine neoplasms are rare tumors with a slow proliferation. They are virtually resistant to many DNA-damaging therapeutic approaches, such as chemo- and external beam therapy, which might...
3.
Taromi S, Lewens F, Arsenic R, Sedding D, Sanger J, Kunze A, et al.
Oncotarget
. 2017 Dec;
8(57):97061-97078.
PMID: 29228593
Small cell lung cancer (SCLC) is an aggressive cancer showing a very poor prognosis because of metastasis formation at an early stage and acquisition of chemoresistance. One key driver of...
4.
Briest F, Grass I, Sedding D, Mobs M, Christen F, Benecke J, et al.
Neuroendocrinology
. 2017 Sep;
107(1):1-23.
PMID: 28910819
Background/aims: The tumor suppressor p53 is rarely mutated in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) but they frequently show a strong expression of negative regulators of p53, rendering these tumors excellent targets...